Model Input Parameters*.

*Further input parameters are provided in the online Technical Appendix and published literature (Suter 2011, Losina 2011).†In order to capture significant pain, we defined pain as those individuals noting functional limitations. Quality of life estimates were derived from general population data, not specifically from TKA recipients.‡Derived from data for quality of life in persons with prosthetic joint infection.§Annual cost of analgesic treatment was added for individuals who did not achieve pain relief from their TKA.||CMS = Centers for Medicare and Medicaid Services.¶Short-term refers to the first year following primary or revision TKA.**Long-term refers to the annual proportion of individuals experiencing a TKA outcome or AE each year following the first year after primary or revision TKA.††Technical failure is the percentage of individuals who required or qualified for revision surgery due to mechanical failure of the prosthesis, with or without associated symptoms.‡‡Pain relief success is the percentage of individuals achieving pain relief without technical failure. In instances of technical failure, pain relief was significantly less than the values reported above.§§Adverse events (AEs) only occurred in the first year after primary or revision TKA.***These values represent the range of failure rates used in the Primary Analysis (20–70% reductions in failure for innovative compared to standard implants). Standard implants had long-term failure rates as high as 5.44% in the sensitivity analysis exploring the impact of higher long-term failure in healthy 50–59-year-olds, producing a failure rate of 4.35% for an innovative implant offering a 20% decrease in long-term failure.†††The implant cost is included in the total first-year cost of TKA.

*进一步的输入参数详见在线技术附录与已发表文献（Suter 2011、Losina 2011）。†为明确界定显著疼痛，本研究将存在功能受限的个体定义为疼痛人群。生活质量评估数据源自普通人群队列，而非专门针对全膝关节置换术（Total Knee Arthroplasty, TKA）受术者的数据集。‡该指标源自假体关节感染患者的生活质量相关数据。§对于未从全膝关节置换术中获得疼痛缓解的个体，需额外计入镇痛治疗的年度成本。||医疗保险与医疗救助服务中心（Centers for Medicare and Medicaid Services, CMS）。¶短期指初次或翻修全膝关节置换术后的第一年内。**长期指初次或翻修全膝关节置换术后第一年后，每年出现全膝关节置换术相关结局或不良事件（Adverse Event, AE）的个体占比。††技术失败率指因假体机械故障（无论是否伴随相关症状）而需要或符合翻修手术指征的个体占比。‡‡疼痛缓解成功率指未发生技术失败且获得疼痛缓解的个体占比。当出现技术失败时，疼痛缓解率将显著低于前文所述数值。§§不良事件仅发生于初次或翻修全膝关节置换术后的第一年内。***本部分数值代表主分析中采用的失败率区间：相较于标准假体，创新型假体的失败率可降低20%至70%。在针对健康50-59岁人群开展的敏感性分析中，标准假体的长期失败率最高可达5.44%；若创新型假体的长期失败率较标准假体降低20%，则其失败率为4.35%。†††假体成本已计入全膝关节置换术的首年度总成本中。